AstraZeneca has invested €25m (£23m) into gene messenger drug development, through a research tie-up with German biotech Ethris.
The FTSE 100 drugmaker has agreed to pay Munich-based Ethris the sum upfront, with further payments and royalties possible depending on development progress.
Ethris, which was founded by two German scientists in 2009, specialises in RNA drugs, which instruct human cells to produce therapeutic proteins.
The alliance with AstraZeneca and its biotech division MedImmune will focus on asthma and other respiratory diseases.
Scientists believe the RNA approach holds potential to treat a range of conditions, including cancer and heart disease.
It is not AstraZeneca’s first investment in the field. Last year the company invested a further $140m (£109m) in RNA specialist Moderna Therapeutics, upping its stake to 9pc.
AstraZeneca is looking to bounce back after a negative readout from its lung cancer drugs trial Mystic last month led to its biggest single day share price fall, wiping £10bn from the company’s market value.
By Iain Withers
Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.
The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.
In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.